First human test of experimental fatty liver pill begins
NCT ID NCT07214870
Summary
This is the first-ever human study to test whether a new experimental drug called NNC4005-0001 is safe and well-tolerated in people. The trial will enroll 60 adults who are overweight and have high levels of fat in their liver. Participants will receive either the experimental drug or a placebo (inactive substance) in a single dose, and researchers will monitor them for about 7-8 months to check for side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Company, Inc
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.